New and Existing Investors Recognize the Company’s Current and Future Impact as it Brokers Strategic Deals to Direct More People to Effective Mental Health Care

NEW YORK, March 3, 2026 — Grow Therapy (Grow), a mental health platform empowering providers to deliver exceptional in-person and online therapy and psychiatric care, today announced it has raised $150 million in Series D financing. This vote of confidence from prominent investors follows Grow’s innovation streak and a deepening of its relationships with health plans, employers, and health systems. The round was led by existing backers TCV and Growth Equity at Goldman Sachs Alternatives, with new investors BCI and Menlo Ventures joining Sequoia, SignalFire, and Transformation Capital.

“Grow has built alliances and capabilities that deliver win-win-win results for clients, providers, and all of our other partners with a stake in mental health care,” said Jake Cooper, CEO and Co-founder of Grow. “This Series D reflects investor confidence in Grow’s ability to execute a high-impact strategy and continue making mental health care more accessible, effective and connected.”

“TCV loves backing great entrepreneurs targeting very large market opportunities. We are excited to continue to partner with Grow on the journey to provide access to, and improvement of, quality mental health care,” said Jay Hoag, Founding General Partner at TCV.

GROWTH AND IMPACT
Over the past five years, more than two million people nationwide have turned to Grow for therapy and medication management. In 2025 alone, Grow facilitated seven million visits, bringing the lifetime total to 10 million therapy and medication management appointments. Grow reports that nine in 10 clients would strongly recommend Grow to a friend, reflected in an 85 Net Promoter Score (NPS), which is considered excellent on a scale of -100 to 100.

Better Care, Better Results, Broader Access
Since its Series C in April 2024, Grow has continued to build a secure, actionable, and measurable mental health platform for providers, partners, and people receiving care, including:

• Advanced tools for providers: Grow strengthened its scheduling, billing and electronic health record (EHR) software and introduced free, clinically guided AI-assisted notes. Since launch, Grow’s data found that provider documentation time has dropped by nearly 70%, while exceeding manual note accuracy.
• Continuous support between visits: Through the Grow mobile app, rated 4.9 stars in the Apple App Store, clients have free access to clinically guided AI tools that support self-reflection between sessions. With a client’s consent, relevant insights can be shared with the provider ahead of the next visit to keep time together focused and productive.
• Outcomes measurement: Grow launched systems to gather evidence-based measures that track client outcomes over time. According to Grow’s internal data, 80% of clients see measurable symptom improvement within 30 days.
• Expanded insurance coverage: Grow expanded from 75 to 125+ health insurer partners, including Medicare and Medicaid. This broad coverage makes mental health care accessible to 220 million people nationwide using the plans they already have. On average, Grow clients pay $21 per visit, and one in three pay $0.
• Deepened critical partnerships: Grow developed flagship partnerships with major insurers, including Guidewell, and its care navigation partner Lucet, focused on shared goals such as improving clinical outcomes, lowering total cost and delivering a better member experience.

“We’re thrilled to back Grow on its mission to deliver breakthrough products and care for mental health. Their technology is grounded in a deep understanding of what people, providers, and business partners need for superior outcomes,” said Matt Murphy, Partner at Menlo Ventures. “Grow has consistently exceeded lofty expectations through world-class execution at scale, and we strongly believe they will define and lead the category for years to come.”

NEW PARTNERSHIPS EXPAND ENTRY POINTS TO CARE

Workplace Mental Health Benefits

Beginning in 2026, Grow will accelerate work with employers to strengthen workplace mental health benefits. Employer-sponsored mental health programs (often called employee assistance programs, or EAPs) and health-plan coverage don’t always connect. As a result, employees may need to switch therapists or pay out of pocket after they’ve used their EAP sessions. Building on its integrations with health plans, Grow helps companies offer a single, connected experience, so employees can seamlessly transition to using their health insurance and keep the same provider after they’ve fully utilized their employer program.

These offerings deliver nationwide coverage, fast access to vetted, licensed clinicians, and flexible virtual and in-person care. Grow’s clinically guided AI tools extend support between sessions, surface useful information, and help patients improve over time. By working alongside employers and their health plan partners, Grow will remove friction and help employees and their families get effective care without interruption.

Additionally, employers need to balance quality and cost. Grow delivers care that is proven effective while keeping payments aligned with what employees expect from their health plans. And rather than a flat fee for every employee regardless of utilization, Grow only charges for care that’s actually delivered, making it easier for employers to invest in mental health with confidence.

Julie Harris, Grow’s VP of Enterprise Partnerships, understands these employer dynamics deeply and is leading the effort to bring something better and more cost-effective to market. “What makes Grow’s value to employers distinct is our ability to balance competing demands,” said Harris. “A mentally healthy workforce is more productive by every measure, but employers also have to contain rising costs. Grow offers a rigorously vetted network that delivers measurable mental health improvements in a model designed to complement, not compete with, existing health plan benefits.”

Health Systems
Grow is also extending its platform to health systems, including Circle Medical. Through Grow, medical teams can coordinate referrals, share relevant context, and help set up for a strong first therapy session. Through these coordinated and collaborative efforts, Grow is supporting a clearer path from screening to treatment and reducing friction when follow-up care is needed.

LOOKING AHEAD
Grow plans to continue deepening integrations across all the paths people take to find mental health care and investing in clinically guided technology to deliver better outcomes. As the platform expands across health plans, health systems and employers, Grow aims to ensure people can get the care they need, no matter where their mental health journey starts.

ABOUT GROW
Grow Therapy (Grow) is a mental health platform empowering providers to deliver exceptional in-person and online therapy and psychiatric care. Its rigorously vetted network of 26,000 providers delivers high-quality care covered by insurance, with 220 million Americans able to access Grow through their health plan. Grow Therapy has raised $328 million, and key investors include Sequoia Capital, Goldman Sachs Alternatives, Transformation Capital, TCV, SignalFire, Plus Capital, BCI and Menlo Ventures. More information about Grow Therapy can be found at growtherapy.com. 

Media Contact: Kristina McPherson ([email protected])

SOURCE Grow Therapy

Agricultural company develops gene edited traits that shifts a crop’s energy from defense to yield

NORWICH RESEARCH PARK, England, March 3, 2026 — ALORA, an agricultural biotechnology company developing gene-edited crop traits that redirect plant energy from stress defense to yield, today announced the appointment of Adam Helms as Chief Executive Officer and the close of a funding round led by the Neglected Climate Opportunities Fund, a subsidiary of the Grantham Environmental Trust, with participation from Toyota Ventures.

Helms joins ALORA as the company advances early results in yield and heat tolerance traits toward broader validation. ALORA’s research has demonstrated yield improvements in rice of up to 1.5x under optimal conditions and 2–4x under extreme heat stress in controlled environments, with initial 2025 United Kingdom field trials confirming open-field performance. The company’s focus in 2026 is reproducing these results across additional genetic backgrounds to support future commercial partnerships.

“ALORA has generated compelling early trait data, and I’m excited to work with this team to advance that science toward commercial relevance,” said Adam Helms, incoming CEO. “Our priority this year is building proof points that matter to partners and investors by validating traits across multiple lines, crops, and geographies to enable substantive industry discussions.”

Founding CEO Luke Young transitions to Chief Technology Officer, where he will lead ALORA’s continued research and development efforts.

“We’re pleased to continue our support of ALORA and welcome Adam to the team,” said Caroline de Bossart, Director at the Grantham Environmental Trust. “His experience building early-stage companies will be valuable as ALORA translates its initial results into a broader validation program.”

ALORA will attend World AgriTech in San Francisco on March 17–18, 2026.

About ALORA

ALORA is an agricultural company utilizing gene editing to develop crop traits that shift a plant’s energy from defense to yield. The company’s work spans controlled environment research and international field trials, with primary operations at the Norwich Research Park, UK. For more information, please visit www.alora.world.

About the Grantham Environmental Trust’s Neglected Climate Opportunities Fund

Neglected Climate Opportunities LLC is a climate-focused venture capital vehicle and a wholly owned subsidiary of the Jeremy and Hannelore Grantham Environmental Trust which, along with its affiliate, the Grantham Foundation for the Protection of the Environment, believe that innovation and technology are the best hope for an enduring future. For more information, please visit www.granthamfoundation.org.

About Toyota Ventures

Toyota Ventures is the early-stage venture capital arm of Toyota. Founded in July 2017, its mission is to discover what’s next for Toyota by helping startups bring disruptive technologies and business models to market quickly. With more than $800 million in assets under management, the firm is dedicated to investing in talented entrepreneurs around the world who are driving innovation in deep technology and climate solutions. For more information about Toyota Ventures and its portfolio companies, please visit www.toyota.ventures.    

Media Contact: [email protected]

SOURCE ALORA Innovations Inc.

LAUSANNE, Schweiz, 3. März 2026 — Xsensio SA, ein Schweizer Deep-Tech-Unternehmen, das Pionierarbeit bei der kontinuierlichen biochemischen Überwachung nahezu in Echtzeit leistet, gab heute den erfolgreichen Abschluss einer überzeichneten Serie-A-Finanzierungsrunde in Höhe von 7 Millionen US-Dollar bekannt. Die Runde wurde von der in San Francisco ansässigen Risikokapitalgesellschaft WI Harper angeführt, mit Beteiligung von Privilège Ventures, dem European Innovation Council und privaten Investoren aus den Vereinigten Staaten, Europa und Asien.

Durch die neue Finanzierung kann Xsensio die Entwicklung und klinische Validierung seiner tragbaren Biosensorik-Plattform Lab-on-Skin© beschleunigen, die dynamische, multimodale biochemische Informationen liefert, um die klinische Entscheidungsfindung im Krankenhaus und darüber hinaus zu unterstützen.

„Diese Serie A ist ein entscheidender Schritt bei der Umsetzung der kontinuierlichen biochemischen Überwachung in reale klinische Umgebungen”, sagte Esmeralda Megally, Geschäftsführerin von Xsensio. „Zum ersten Mal können Kliniker auf wichtige kontinuierliche biochemische Daten in Echtzeit zugreifen, Informationen, die in der Vergangenheit am Ort der Behandlung nicht verfügbar waren. Dadurch kann die Art und Weise, wie Patienten überwacht und behandelt werden, grundlegend verbessert werden.”

Parallel dazu kündigte Xsensio eine langfristige Zusammenarbeit mit Texas Instruments, einem weltweit führenden Unternehmen der Halbleitertechnologie, an. Diese Zusammenarbeit bringt einzigartiges Fachwissen in den Bereichen CMOS-Integration, Miniaturisierung und Großserienfertigung von Biosensoriksystemen mit sich und stärkt die industrielle Skalierbarkeit von Xsensio.

„Unsere Zusammenarbeit mit Texas Instruments stärkt unseren Weg zu fortschrittlicher, skalierbarer Halbleitertechnologie erheblich”, fügte Adrian Ionescu, technischer Leiter von Xsensio, hinzu. „Durch die Kombination unserer Biosensorik-Innovation mit der Weltklasse-Halbleiterexpertise bauen wir eine Plattform auf, die nicht nur für die klinische Anwendung, sondern auch für den zuverlässigen und kostengünstigen Einsatz konzipiert ist.”

„Wir glauben, dass Xsensio eine neue Kategorie der tragbaren Biosensorik definiert. Angesichts der großen Fortschritte und des Marktpotenzials des Unternehmens freuen wir uns, diese Investitionsrunde zu leiten”, sagte Wilson Wu, Partner bei WI Harper. 

„Die kontinuierliche biochemische Überwachung stellt einen bedeutenden Wandel von intermittierenden Messungen hin zu Erkenntnissen in Echtzeit dar, und Xsensio ist einzigartig positioniert, um diesen Wandel anzuführen”, sagte Jaqueline Ruedin Rüsch, Vorsitzende des Verwaltungsrats.

Informationen zu Xsensio

Xsensio ist ein Schweizer Deep-Tech-Unternehmen, das die tragbare Biosensor-Plattform Lab-on-Skin© entwickelt, um kontinuierlich biochemische Informationen in Echtzeit für eine personalisierte und präventive Gesundheitsversorgung zu liefern. Das aus führender akademischer Forschung hervorgegangene Unternehmen arbeitet mit Referenzkrankenhäusern und Industriepartnern zusammen, um Patienten im Krankenhaus und darüber hinaus klinisch sinnvolle Biosensorik-Innovationen zu bieten. Xsensio wurde vom TIME Magazine als eines der weltweit führenden HealthTech-Unternehmen des Jahres 2025 ausgezeichnet.

Medienkontakt
Esmeralda Megally, Geschäftsführerin & Mitbegründerin
Xsensio SA
[email protected]
www.xsensio.com

Foto: https://mma.prnewswire.com/media/2923220/Xsensio_Lab_On_Skin.jpg
Logo: https://mma.prnewswire.com/media/2923219/Xsensio_Logo.jpg

LAUSANNE, Suisse, 3 mars 2026 — Xsensio SA, une société suisse de haute technologie pionnière dans la surveillance biochimique continue en temps quasi réel, a annoncé aujourd’hui la clôture d’un tour de financement de série A avec une souscription excédentaire de 7 millions de dollars. L’opération a été menée par la société de capital-risque WI Harper, basée à San Francisco, avec la participation de Privilège Ventures, du Conseil européen de l’innovation et d’investisseurs privés des États-Unis, d’Europe et d’Asie.

Ce nouveau financement permettra à Xsensio d’accélérer le développement et la validation clinique de sa plateforme de biodétection portable Lab-on-Skin©, conçue pour fournir des informations biochimiques dynamiques et multimodales afin d’aider à la prise de décision clinique à l’hôpital et ailleurs.

« Cette série A marque une étape cruciale dans la mise en œuvre de la surveillance biochimique continue dans des environnements cliniques réels », a déclaré Esmeralda Megally, PDG de Xsensio. « Pour la première fois, les cliniciens peuvent accéder en temps réel à des données biochimiques clés et continues, informations qui n’étaient pas disponibles jusqu’à présent sur le lieu des soins. Cette capacité a le potentiel d’améliorer fondamentalement la façon dont les patients sont suivis et traités. »

Parallèlement, Xsensio a annoncé une collaboration à long terme avec Texas Instruments, un leader mondial de la technologie des semi-conducteurs. Cette collaboration apporte une expertise unique en matière d’intégration CMOS, de miniaturisation et de fabrication à grande échelle de systèmes de biodétection, renforçant ainsi l’évolutivité industrielle de Xsensio.

« Notre collaboration avec Texas Instruments renforce considérablement notre voie vers une technologie de semi-conducteurs avancée et évolutive », a ajouté Adrian Ionescu, directeur technique de Xsensio. « En combinant notre innovation en matière de biodétection et notre expertise de classe mondiale dans le domaine des semi-conducteurs, nous construisons une plateforme conçue non seulement pour avoir un impact clinique, mais aussi pour être déployée de manière fiable et rentable. »

« Nous pensons que Xsensio définit une nouvelle catégorie de biodétection portable. Compte tenu de la forte progression de l’entreprise et de son potentiel commercial, nous sommes ravis de diriger ce tour d’investissement », a déclaré Wilson Wu, associé chez WI Harper. 

« La surveillance biochimique continue représente un changement majeur, passant de mesures intermittentes à des informations en temps réel, et Xsensio est particulièrement bien placée pour mener cette transformation », a déclaré Jaqueline Ruedin Rüsch, présidente du conseil d’administration.

À propos de Xsensio

Xsensio est une société suisse de haute technologie qui développe la plateforme de biodétection portable Lab-on-Skin© pour fournir des informations biochimiques en continu et en temps réel pour des soins de santé personnalisés et préventifs. Issue de la recherche universitaire de pointe, l’entreprise collabore avec des hôpitaux de référence et des partenaires industriels afin d’apporter des innovations cliniquement significatives en matière de biodétection aux patients à l’hôpital et au-delà. Xsensio a été reconnue par TIME comme l’une des meilleures entreprises mondiales dans le domaine des technologies de la santé en 2025.

Contact médias
Esmeralda Megally, PDG et cofondatrice
Xsensio SA
[email protected]
www.xsensio.com

Photo : https://mma.prnewswire.com/media/2923220/Xsensio_Lab_On_Skin.jpg
Logo : https://mma.prnewswire.com/media/2923219/Xsensio_Logo.jpg

SINGAPORE, March 2, 2026 — Dyna.Ai, a leading AI solutions company headquartered in Singapore, today announced the close of an undisclosed eight-figure multimillion-dollar (USD) Series A round led by Lion X Ventures, a Singapore based venture capital fund, advised by OCBC Bank’s Mezzanine Capital Unit.

The round also included participation from ADATA, a Taiwan-listed technology company, a Korean financial institution, and a group of finance veterans with decades of industry experience.

The funding will accelerate the deployment of Dyna.Ai’s Agentic AI solutions, helping enterprises turn AI pilots into fully operational systems that deliver measurable business outcomes.

Dyna.Ai’s Results-as-a-Service approach prioritizes measurable revenue outcomes and has been validated across regulated financial services and enterprise environments. Its solutions combine domain-specific expertise, AI agent builders, task-ready AI agents, and fully operational agentic applications capable of executing tasks within defined workflows while ensuring compliance, controls, and accountability. The solutions are already deployed in live enterprise environments, helping organizations including leading global and regional banks as well as financial institutions across Asia, Americas, and the Middle East streamline operations, enhance customer, experience, and optimize employee workflows.

The investment reflects confidence in Dyna.Ai’s execution-led approach, supporting continued delivery, governance, and long-term platform development. This momentum comes as Southeast Asia’s AI market is projected to exceed US $16 billion by 2033, which is indicative of the opportunity to augment talent with AI capabilities. Singapore continues to be a regional leader in AI with initiatives to support the responsible development of AI technology in addition to a commitment to invest over S$1 billion (US $778.8 million) in public artificial intelligence research over the next five years. 

“Fundamentally, we are innovative-driven and commercial people who have experienced the same operational challenges we are solving today,” said Tomas Skoumal, Chairman and Co-Founder of Dyna.Ai. “While much of the industry was focused on how broadly AI could be applied, we doubled down early on a specific, pressing problem and built with outcomes in mind. That focus continues to guide how we work with enterprises today and has built trust with C-suite leaders across institutions around the world.”

“Enterprise AI is entering a phase where execution and measurable outcomes matter more than experimentation,” said Irene Guo, CEO of Lion X Ventures. “Dyna.Ai differentiates itself through strong domain expertise, operational discipline, and the ability to deploy agentic AI within complex, regulated enterprise environments. We are pleased to support the team as they scale across global enterprise and financial services markets.”

“Across the region, we’re seeing a shift in how enterprises approach AI,” said Cynthia Siantar, Head of Investor Relations and General Manager for Singapore and Hong Kong. “The focus has moved past pilots and experimentation to how AI can be deployed in day-to-day operations and deliver real outcomes. With Dyna.Ai, we are proud to take a Singapore built platform to leading BFSI enterprises in the region and across the world.”

Founded in 2024, Dyna.Ai was built to address structural bottlenecks in enterprise operation, adopting a results-driven approach that prioritizes commercial outcomes over experimentation as enterprises move from proof-of-concepts to enterprise-grade AI.

About Dyna.Ai

Dyna.Ai is a leading AI-as-a-Service company headquartered in Singapore, delivering enterprise-grade AI solutions that turn advanced AI into measurable business results. The company provides AI-powered products and services that enhance customer experience (CX), improve employee experience (EX), and optimize core business operations, with solutions designed for practical enterprise deployment. With a global presence across Asia, the Middle East, and the Americas, Dyna.Ai powers financial institutions, contact centers, and enterprises worldwide.

SOURCE Dyna.Ai

Strategic and institutional investors including Yara International back PlasmaLeap to develop Green Fertiliser Technology

• Funding supports first-of-a-kind on-farm fertiliser deployments in Australia, and advances core technology for eFuels & industrial chemicals products.
• Technology addresses emissions from ammonia and nitrogen fertiliser production, a large source of CO2 globally.

SYDNEY, March 2, 2026 — PlasmaLeap Technologies, the Australian company pioneering zero-emissions production of ammonia and nitric acid, has secured almost A$30 million (US$20 million) in new funding from a group of strategic and institutional investors, which was led by the Gates Foundation, Investible and Yara Growth Ventures, the venture arm of Yara International, a world leading integrated nitrogen fertilisers producer.

The Series A round, which closed in January, also included Twynam, GrainCorp Ventures, Uniseed/UniSuper, Artesian, SVG Ventures and Agnition Ventures, part of New Zealand fertiliser co-operative Ravensdown. The proceeds will be used to progress first-of-a-kind fertiliser hubs in New South Wales and Tasmania, expand field trials, and further develop PlasmaLeap’s core technology. Funding will also support longer-term applications in sustainable fuels and energy systems.

PlasmaLeap’s technology, which was spun out of the University of Sydney, enables farmers to produce sustainable nitrogen fertiliser directly on their farms or at local hubs, reducing emissions, input costs, and supply-chain dependency. Nitrogen fertiliser production, transport, and application accounts for a significant share of global industrial emissions (~2.5% global CO2e)^[1], driven by fossil fuel-intensive manufacturing, long-haul transport, and chemical losses at the crop. Moreover, fertiliser access and cost vary dramatically across the globe, with the retail price in certain parts of sub-Saharan Africa being nearly double the world fob^[2] price, due to issues around importation, logistics, and financing.

“The backing of these strategic and institutional investors is strong validation of both the PlasmaLeap technology and the scale of the opportunity,” said Frere Byrne, CEO & Co-founder of PlasmaLeap. “This funding allows us to move from successful trials into real-world deployment, demonstrating how clean, decentralised fertiliser and chemical production can transform agriculture, reduce emissions and guarantee sovereign security of critical resources like food and fuel.”

“PlasmaLeap has developed a breakthrough platform for fertiliser with lower CO2 emissions, delivering step-change improvements in energy efficiency. We see strong potential for this technology to scale competitively and reduce the climate impact of farming,” said Stian Nygaard, Investment Director at Yara Growth Ventures.

“Decarbonized and distributed liquid nitrogen production is the new frontier in agriculture. The PlasmaLeap technology can unlock opportunities for scaling-up fertigation and precision farming globally,” said Martin Debaig, Fertigation Director at Yara International. 

“PlasmaLeap is unlike anything we’ve seen in the green ammonia space and their technology is defining a new category in distributed sustainable fertiliser production. We first met the team through Greenhouse Tech Hub. As our tenth investment in a Greenhouse member, it reinforces our model of pairing early access and capital with a purpose-built innovation ecosystem,” said Ben Lindsay, Investment Principal at Investible.

The global market for ammonia, the primary ingredient in most nitrogen fertilisers, is worth approximately US$69 billion a year^[3], and projected to triple in size over the next 20 years.

PlasmaLeap’s patented reactor technology produces ammonia and nitrate using only air, water and renewable electricity. The company’s modular systems are scalable and designed to integrate with existing fertiliser supply chains.

The technology has the potential to improve national food security, reduce exposure to international price shocks, and reduce and stabilise input costs for growers. This capability becomes increasingly critical as resource availability and geopolitical instability continue to impact global fertiliser markets.

It is also expected to generate high quality carbon credits through the decarbonisation benefits it brings through production, transport and application-related emissions reduction. PlasmaLeap is considering a number of carbon standard methodologies that may be applied to credit generation from its technology.

PlasmaLeap continues to advance its technology platform with a focus on efficiency, scalability and commercial deployment. It also has potential to produce synthetic hydrocarbons from biogas, syngas, or other low-carbon feedstocks, supporting decarbonisation pathways for hard-to-abate sectors.

–Ends–

About PlasmaLeap:

PlasmaLeap designs, manufactures, and distributes the world’s most advanced zero-emissions modular chemical reactors for hard-to-abate industries including agriculture, energy, and transport. Our mission is to build accessible, sustainable technology for global fuel and chemical production. Headquartered in Sydney, PlasmaLeap’s state-of-the-art chemical plants are disrupting the chemical sector, using only air, water and electricity to create valuable fuels, fertilisers, and industrial chemicals with marked-leading energy performance and production rates. PlasmaLeap is a grant recipient of The Gates Foundation, the 2025 winner of SVG Thrive, a finalist in Petronas Future Tech 4.0, and a 2024 Australian nominee for the Earthshot prize.

[1] International Fertiliser Association data.

[2] Free on Board.

[3] Arkwright Market Study 2021.

Procode AI’s Coding Copilot enables medical coders to code 90% faster and with much greater accuracy by translating operative reports to billing and diagnostic codes. The company has already added $2M of ARR in five months post-acquisition, demonstrating the profound benefit to providers: fewer coding-related denials, fewer AR days, and maximized reimbursements.

“Our cofounder is a surgeon. Our mission is personal and singular: create the first, best, and largest AI-powered revenue cycle management company for surgeons in private practice,” said Cripe. “The Auctus Group is a tech-forward, missionary team who want to build the next generation biller with us.”

Procode AI’s technology transforms The Auctus Group’s providers’ experience and revenue:

• Procode AI Coding Copilot reduces coding-related denials, maximizes payments
• Auctus Provider App puts real-time financial and claims data at surgeons’ fingertips
• AR/Denials Management Engine that’s faster, clearer, and more reliable by leveraging AI for AR decision making, payment posting, charge posting and other AR processes

“As a surgeon, choosing a medical biller means trusting all of your insurance-based income to one company,” said Dr. Rezzadeh. “At Procode, we’re building technology that ensures that providers are reimbursed fairly for procedures that they perform, and that they are reimbursed faster than ever before.”

The Auctus Group was founded in 2012 by John Gwin, who will continue to lead the RCM business. “Most RCM AI products are vaporware,” said Gwin. “As CEO of The Auctus Group and a longtime HBMA leader, I’ve searched for AI technology that can better equip our team to deliver better billing outcomes for clients and, in Procode, we finally found that.”

About Procode AI

Procode AI is an AI-powered revenue cycle management (RCM) company for surgeons in private practice. Founded in 2024, Procode AI builds intelligent billing infrastructure that removes the administrative burden and uncertainty of reimbursement, giving surgeons confidence in their revenue and the freedom to focus on patient care. Procode AI’s Coding Copilot, AR/Denial Management Engine, and Auctus Provider App automate coding, streamline claims, and give providers transparency into their revenue cycle. The company has raised $4M in venture funding and acquired The Auctus Group, a leading RCM firm, serving more than 300 plastic surgery and dermatology providers.

Download the Auctus Provider App

iOS
https://apps.apple.com/us/app/auctus-providers/id6751704100

Android
https://play.google.com/store/apps/details?id=com.procodeai.procodeaicompanion&hl=en_US

SOURCE Procode Inc.

LAUSANNE, Switzerland, March 2, 2026 — Xsensio SA, a Swiss deep-tech company pioneering near real-time continuous biochemical monitoring, today announced the successful closing of a $7M oversubscribed Series A financing round. The round was led by San Francisco-based venture capital firm WI Harper, with participation from Privilège Ventures, the European Innovation Council, and private investors across the United States, Europe, and Asia.

The new funding will enable Xsensio to accelerate the development and clinical validation of its Lab-on-Skin© wearable biosensing platform, designed to provide dynamic, multi-modal, biochemical information to support clinical decision-making in the hospital and beyond.

“This Series A marks a pivotal step in translating continuous biochemical monitoring into real clinical environments,” said Esmeralda Megally, CEO of Xsensio. “For the first time, clinicians can access key continuous biochemical data in real time, information that has historically been unavailable at the point of care. This capability has the potential to fundamentally improve how patients are monitored and treated.”

In parallel, Xsensio announced a long-term collaboration with Texas Instruments, a global leader in semiconductor technology. This collaboration brings unique expertise in CMOS integration, miniaturization, and large-scale manufacturability of biosensing systems, further strengthening Xsensio’s industrial scalability.

“Our collaboration with Texas Instruments significantly strengthens our path to advanced, scalable semiconductor technology,” added Adrian Ionescu, CTO of Xsensio. “By combining our biosensing innovation with world-class semiconductor expertise, we are building a platform designed not only for clinical impact, but also for reliable, cost-effective deployment.”

“We believe Xsensio is defining a new category in wearable biosensing. Given the company’s strong progress and market potential, we are excited to be leading this investment round,” said Wilson Wu, Partner at WI Harper. 

“Continuous biochemical monitoring represents a major shift from intermittent measurements to real-time insight, and Xsensio is uniquely positioned to lead this transformation,” said Jaqueline Ruedin Rüsch, Chair of the Board.

About Xsensio

Xsensio is a Swiss deep-tech company developing the Lab-on-Skin© wearable biosensing platform to deliver continuous, real-time biochemical information for personalized and preventive healthcare. Spun out of leading academic research, the company collaborates with reference hospitals and industrial partners to bring clinically meaningful biosensing innovation to patients in the hospital and beyond. Xsensio has been recognized by TIME as one of the World’s Top HealthTech Companies of 2025.

Media Contact
Esmeralda Megally, CEO & Co-Founder
Xsensio SA
[email protected]
www.xsensio.com

Photo: https://mma.prnewswire.com/media/2923220/Xsensio_Lab_On_Skin.jpg
Logo: https://mma.prnewswire.com/media/2923219/Xsensio_Logo.jpg

SOURCE XSENSIO

Die von Wellington Management geführte Finanzierungsrunde bringt die Gesamtfinanzierung von Encord auf 110 Millionen Dollar. Das Unternehmen verzeichnete in den letzten zwölf Monaten ein 10-faches Wachstum des Umsatzes mit physischer KI

SAN FRANCISCO, 2. März 2026   — Encord, das Dateninfrastrukturunternehmen für physische KI, gab heute eine Serie-C-Finanzierungsrunde in Höhe von 60 Millionen US-Dollar unter der Leitung von Wellington Management bekannt, wodurch sich die Gesamtfinanzierung des Unternehmens auf 110 Millionen US-Dollar erhöht. Neben den bestehenden Investoren Y Combinator, CRV, N47, Crane Venture Partners und Harpoon Ventures beteiligten sich auch die neuen Investoren Bright Pixel Capital und Isomer Capital an der Runde.

Die Investition wird Encord dabei helfen, seine KI-native Dateninfrastrukturplattform zu skalieren, die KI-Teams dabei unterstützt, die multimodalen Daten zu verwalten, zu kuratieren, zu kommentieren und abzugleichen, auf die physische KI-Systeme angewiesen sind. Dazu gehören Audio-, Video-, Bild- und Sensordaten, 3D-Punktwolken und andere Formate, für die herkömmliche Datenplattformen nicht ausgelegt waren.

Encord arbeitet mit über 300 KI-Teams weltweit zusammen, darunter Woven by Toyota, Skydio, AXA Financial und zahlreiche physische KI- und Frontier-Labs. Das Unternehmen verzeichnete in den letzten zwölf Monaten aufgrund des Anstiegs der physischen KI ein erhebliches Wachstum bei Umsatz und Datenvolumen auf seiner Plattform.

Der Wendepunkt in der physischen KI

Die Serie-C-Finanzierungsrunde von Encord erfolgt zu einem Zeitpunkt, an dem physische KI, die Roboter, autonome Fahrzeuge, Drohnen und andere Systeme in der realen Welt antreibt, in eine neue, explosive Wachstumsphase eintritt. Nach jahrelangen Labordemonstrationen und Pilotprogrammen gehen diese Systeme nun in Produktion. Analysten gehen davon aus, dass allein in den nächsten vier Jahren mehr als 400 Millionen KI-Roboter in Betrieb gehen werden und dass der Umfang der physischen KI-Industrie im gleichen Zeitraum 30 Milliarden Dollar übersteigen wird.

Im Gegensatz zu Large Language Models, die im offenen Internet trainiert wurden, müssen physische KI-Modelle aus proprietären Daten lernen, darunter Sensor-Feeds, Video, Robotertelemetrie, im Feld erfasste Grenzfälle und andere Quellen. Die Speicherung und Verarbeitung dieser Daten erfordert mehr Rechenleistung als die Speicherung und Verarbeitung von Text.

Diese Daten organisieren sich nicht von selbst. Um die richtigen Daten in die Modelle einzuspeisen und falsche Daten herauszufiltern – und das kontinuierlich und in großem Umfang – ist eine speziell entwickelte KI-native Dateninfrastruktur erforderlich.

„Alle richten sich darauf aus, größere Modelle zu bauen”, sagt Ulrik Stig Hansen, Mitbegründer und Mitgeschäftsführer von Encord. „Aber bei der physischen KI ist der Engpass nicht die Modellgröße. Es geht um Datenbereitschaft. Selbst das ausgefeilteste Modell der Welt wird versagen, wenn die ihm zugeführten Daten unvollständig, inkonsistent oder nicht mit den realen Bedingungen abgestimmt sind. Das ist das Problem, das wir lösen.”

Encord verzeichnet eine steigende Nachfrage, da sich die physische KI von der Experimentierphase zum Einsatz bewegt:

• Die Daten auf der Plattform des Unternehmens sind innerhalb von zwölf Monaten von 1 Petabyte auf über 5 Petabyte angewachsen – das sind dreimal mehr als die Daten, die zum Training von GPT-4 verwendet wurden
• Der Umsatz mit physischen KI-Kunden ist im gleichen Zeitraum um das 10-fache gestiegen

Die physische KI-Plattform von Encord ermöglicht es führenden KI-Unternehmen und -Teams, Daten über den gesamten Lebenszyklus eines Modells hinweg zu erfassen, zu organisieren und weiterzugeben. Die Software von Encord wurde entwickelt, um alle Aufgaben im Bereich der Datenautomatisierung und -verarbeitung zu bewältigen, mit denen physische KI-Unternehmen konfrontiert sein können: von der Erleichterung der Datengenerierung in der Vorbereitungsphase bis hin zur Anpassung von Modellen anhand von menschlichem Feedback.

Bill Tinney ist leitender Direktor für KI-Produktmanagement und Partnerschaften bei Vantor, einem Kunden von Encord. Er erklärte: „Bei Vantor entwickeln wir KI für kritische Infrastrukturen und nationale Sicherheit – wir benötigten eine Datenplattform, die unseren Ambitionen gerecht wird. Encord bietet uns eine einheitliche Datenschicht, die sich an die Komplexität unserer Geodaten-Workflows anpasst, von der Kuratierung über die Annotation bis hin zur Auswertung, ohne dass es zu einer Fragmentierung der Tools kommt. Für KI-Teams in der Produktion ist die Art und Weise, wie sie ihre Daten operationalisieren, ein entscheidender Wettbewerbsvorteil.”

Eric Landau, Mitbegründer und Mitgeschäftsführer von Encord, sagte, dass die Finanzierung die Produktentwicklung und die Expansion in neue Märkte beschleunigen wird. „Unternehmen, die im Bereich der physischen KI gewinnen, haben etwas verstanden, was andere gerade erst zu begreifen beginnen: Das Modell ist nur so gut wie die Daten, die ihm zugrunde liegen. Wir bauen die Infrastruktur auf, die diese Daten nutzbar macht – nicht nur einmal, sondern kontinuierlich, wenn diese Systeme in der realen Welt lernen und sich verbessern.”

Informationen zu Encord

Encord ist die universelle Datenschicht für KI. Die Plattform unterstützt KI-Teams dabei, ihre Modelle mit den richtigen Daten zu trainieren und auszuführen – durch Verwaltung, Kuratierung, Kommentierung und Abstimmung von Daten über den gesamten KI-Lebenszyklus hinweg. Encord arbeitet mit über 300 führenden KI-Teams zusammen, darunter Woven by Toyota, AXA und Skydio.

Medienkontakt:
Chris Clemens
Nexios Communications Strategies
[email protected]

Logo – https://mma.prnewswire.com/media/2798765/Encord_Logo.jpg